First Time Loading...
C

Concord Biotech Ltd
NSE:CONCORDBIO

Watchlist Manager
Concord Biotech Ltd
NSE:CONCORDBIO
Watchlist
Price: 1 513 INR -2.59% Market Closed
Updated: May 9, 2024
Section:
 

Wall Street
Price Targets

CONCORDBIO Price Targets Summary
Concord Biotech Ltd

Wall Street analysts forecast CONCORDBIO stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for CONCORDBIO is 1 598.6 INR with a low forecast of 1 424.1 INR and a high forecast of 1 806 INR.

CONCORDBIO Lowest Forecast
Wall Street Target
1 424.1 INR
6% Downside
CONCORDBIO Average Forecast
Wall Street Target
1 598.6 INR
6% Upside
CONCORDBIO Highest Forecast
Wall Street Target
1 806 INR
19% Upside
Lowest
Price Target
1 424.1 INR
6% Downside
Average
Price Target
1 598.6 INR
6% Upside
Highest
Price Target
1 806 INR
19% Upside
Concord Biotech Ltd Competitors:
Price Targets
019170
Shinpoong Pharmaceutical Co Ltd
58% Downside
B
3613
Beijing Tong Ren Tang Chinese Medicine Co Ltd
59% Upside
E
EAPI
Euroapi SAS
57% Upside
600594
Guizhou Yibai Pharmaceutical Co Ltd
52% Upside
019170
Shinpoong Pharmaceutical Co Ltd
58% Downside
B
3613
Beijing Tong Ren Tang Chinese Medicine Co Ltd
59% Upside
E
EAPI
Euroapi SAS
57% Upside
600594
Guizhou Yibai Pharmaceutical Co Ltd
52% Upside
AUROPHARMA
Aurobindo Pharma Ltd
5% Upside
TARO
Taro Pharmaceutical Industries Ltd
3% Upside

Revenue
Forecast

Revenue Estimate
Concord Biotech Ltd

For the last 2 years the compound annual growth rate for Concord Biotech Ltd's revenue is 18%. The projected CAGR for the next 3 years is 22%.

18%
Past Growth
22%
Estimated Growth
N/A
Estimates Accuracy
N/A
Average
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
Concord Biotech Ltd

For the last 2 years the compound annual growth rate for Concord Biotech Ltd's operating income is -2%. The projected CAGR for the next 3 years is 29%.

-2%
Past Growth
29%
Estimated Growth
N/A
Estimates Accuracy
N/A
Average
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
Concord Biotech Ltd

For the last 2 years the compound annual growth rate for Concord Biotech Ltd's net income is 1%. The projected CAGR for the next 3 years is 29%.

1%
Past Growth
29%
Estimated Growth
N/A
Estimates Accuracy
N/A
Average
What are analyst estimates?

See Also

Summary
CONCORDBIO intrinsic value, competitors valuation, and company profile.
DCF Valuation
CONCORDBIO stock valuation using Discount Cash Flow valuation method.
Relative Valuation
CONCORDBIO stock valuation using valuation multiples.
Wall Street Estimates
CONCORDBIO price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
CONCORDBIO stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is CONCORDBIO's stock price target?
Price Target
1 598.6 INR

According to Wall Street analysts, the average 1-year price target for CONCORDBIO is 1 598.6 INR with a low forecast of 1 424.1 INR and a high forecast of 1 806 INR.

What is Concord Biotech Ltd's Revenue forecast?
Projected CAGR
22%

For the last 2 years the compound annual growth rate for Concord Biotech Ltd's revenue is 18%. The projected CAGR for the next 3 years is 22%.

What is Concord Biotech Ltd's Operating Income forecast?
Projected CAGR
29%

For the last 2 years the compound annual growth rate for Concord Biotech Ltd's operating income is -2%. The projected CAGR for the next 3 years is 29%.

What is Concord Biotech Ltd's Net Income forecast?
Projected CAGR
29%

For the last 2 years the compound annual growth rate for Concord Biotech Ltd's net income is 1%. The projected CAGR for the next 3 years is 29%.

ALPHA SPREAD
Join more than 135,700+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.